Hepalink Pharmaceutical Group Limited-B (02142) announced that the Company received the notice of termination of the agreement related to Cullinan's termination...
According to the announcement released by Hepalink Pharmaceutical Group Limited-B (02142), the Company has received a termination notice from Cullinan regarding the termination of the agreement, which will take effect on November 3, 2024. Harbour has no obligation to refund any amount received under the agreement before termination. Harbour will regain the global rights of HBM7008 and continue to explore other development and potential commercial opportunities.